Lin, Simeng;
Kennedy, Nicholas;
Saifuddin, Aamir;
Sandoval, Diana Muñoz;
Reynolds, Catherine;
Seoane, Rocio Castro;
Kottoor, Sherine;
... Ahmad, Tariq; + view all
(2021)
Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients.
Research Square: Durham, NC, USA.
Preview |
Text
Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients.pdf - Accepted Version Download (1MB) | Preview |
Abstract
To inform healthcare policy for immunosuppressed patients there is a need to define SARS-CoV-2 vaccine responses. Here we report SARS-CoV-2 vaccine-induced antibody and T cell responses in patients treated with anti-tumour necrosis factor (anti-TNF), a commonly used biologic in inflammatory diseases, compared to patients treated with vedolizumab, a gut-specific antibody targeting integrin a4b7 that does not impair systemic immunity. In anti-TNF recipients, the magnitude of anti-SARS-CoV2 antibodies was reduced five-fold, and rapidly decayed towards the seroconversion threshold by 14 weeks after second dose of vaccine. In contrast, anti-SARS-CoV-2 antibodies were sustained up to 16 weeks in vedolizumab-treated patients. Anti-SARS-CoV2 antibody decay was not observed in vaccinated patients previously infected with SARS-CoV-2. T cell responses were absent in one-fifth of anti-TNF and vedolizumab-treated patients after a second dose of either vaccine. Our data have important implications for anti-TNF recipients, including the need for vaccine prioritization, booster doses, and social distancing strategies.</p>
| Type: | Working / discussion paper |
|---|---|
| Title: | Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.21203/rs.3.rs-755879/v1 |
| Publisher version: | https://doi.org/10.21203/rs.3.rs-755879/v1 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. |
| Keywords: | SARS-CoV-2, immune-mediated inammatory diseases, inammatory bowel disease, anti-TNF therapy, iniximab, vedolizumab, immunosuppressant, vaccine, ChAdOx1 nCoV-19, BNT162b2, durability,CLARITY, T-Lymphocytes |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inst for Liver and Digestive Hlth |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10212759 |
Archive Staff Only
 |
View Item |
